Design Therapeutics
DSGN
137 hedge funds and large institutions have $626M invested in Design Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 61 increasing their positions, 32 reducing their positions, and 16 closing their positions.
254,233% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $9K
91% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 32
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
55% more capital invested
Capital invested by funds: $404M → $626M (+$222M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more funds holding
Funds holding: 125 → 137 (+12)
7.74% more ownership
Funds ownership: 61.59% → 69.33% (+7.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$22.6M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$14.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.1M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$12.9M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$31.6M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$8.35M |
| 3 |
AC
Almitas Capital
Santa Monica,
California
|
-$6.28M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.44M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.42M |
DSGN Hedge Fund Activity: Q2 2026 in Review
137 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2026, worth a combined $626M — up 55% from $404M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DSGN positions and 16 closed out — a net gain of 13 holders — while 61 added to existing stakes and 32 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $22.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $31.6M sold.
- 137 institutional investors held Design Therapeutics (DSGN) as of Q2 2026, up from 125 in Q1 2026.
- Funds reported $626M of Design Therapeutics stock for Q2 2026, up 55% quarter-over-quarter.
- 29 funds opened new Design Therapeutics positions in Q2 2026 and 16 closed out, a net change of +13 holders.
- The largest Design Therapeutics buyer in Q2 2026 was Frazier Life Sciences Management, an estimated $22.6M added.
- The largest Design Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $31.6M sold.
Based on aggregated 13F filings for Q2 2026.